At what enterprise value was CORDENPHARMA acquired in 2022?

You can find the full valuation details of CORDENPHARMA on mynth capital. The transaction's Enterprise Value is estimated to be in the range of 1b - 4b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the Healthcare & Pharma industry currently tracks an average EBITDA multiple of 14.8x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of CORDENPHARMA when it was acquired by ASTORG?

The estimated EV/EBITDA multiple for CORDENPHARMA is in the range of 5x - 12x. For comparison, the Healthcare & Pharma sector currently shows an average EBITDA multiple of 14.8x. Join our community for free to access full valuation data and industry trends.

When was CORDENPHARMA acquired by ASTORG?

CORDENPHARMA was acquired by ASTORG in 2022.

What was the EBITDA of CORDENPHARMA during the acquisition?

CORDENPHARMA's EBITDA is estimated to be in the range of 250M - 500M EUR. Join our community for free to access complete and exact deal data.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the CORDENPHARMA acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the CORDENPHARMA deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://www.astorg.com/news/corden-news#:~:text=Basel%20%2D%20Astorg%2C%20a%20leading%20European,highly%20differentiated%20capabilities%20in%20Active

← DATABASE

Home Database Healthcare & PharmaCORDENPHARMA

05/2022

ASTORG takes majority stake in CORDENPHARMA

SWITZERLAND Life Sciences / Pharma & Biotech / CDMO EV 1b - 4b EUR

Context

Astorg has entered into an agreement to acquire CordenPharma from International Chemical Investors Group (ICIG), a leading pharmaceutical contract development and manufacturing organization (CDMO) specializing in complex drug development and manufacturing. CordenPharma covers the full pharmaceutical lifecycle, from early-stage development through to large-scale commercial production. The company operates a diversified technology platform spanning peptides, lipids and carbohydrates, highly potent active pharmaceutical ingredients (HPAPIs), injectables and small molecules. This multi-technology setup enables CordenPharma to address increasingly complex pharmaceutical requirements across high-growth therapeutic areas including oncology, metabolic diseases and advanced modalities. CordenPharma operates an integrated industrial footprint with R&D and manufacturing sites across Europe and the United States, providing end-to-end development, scale-up and multi-site production capabilities. The group serves a broad base of leading global pharmaceutical and biotechnology customers. As part of the transaction, management and founding shareholders are expected to reinvest alongside Astorg, reflecting strong alignment around the company’s future growth strategy.

CORDENPHARMA, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, representing a LOGIN to the average currently observed in the Healthcare & Pharma sector (14.8x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in Healthcare & Pharma market trends

Target

CordenPharma is a global pharmaceutical CDMO (Contract Development and Manufacturing Organization) headquartered in Switzerland. The company supports pharmaceutical and biotechnology clients across the entire drug development lifecycle, from early-stage research through to commercial manufacturing. CordenPharma operates a global industrial network of 11 manufacturing and R&D sites across Europe and North America. It serves more than 290 blue-chip pharmaceutical and biotech customers through multiple technology platforms, including small molecules, injectables, lipids, and peptides.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2022

2021

Other operations with CORDENPHARMA

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
06/2026	CORDENPHARMA	AMBIOPHARM	UNITED STATES	Life Sciences	CordenPharma, backed by private equity firm Astorg, entered into an agreement to acquire AmbioPharm, a US-based CDMO specializing in complex peptide APIs with manufacturing sites in the United States and China. The transaction is part of CordenPharma’s broader strategy to strengthen its position as a global leader in peptide therapeutics manufacturing, a high-growth segment driven by next-generation pharmaceutical innovation, including GLP-1 and other advanced peptide-based therapies. The acquisition adds complementary capabilities across solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), hybrid synthesis technologies, as well as downstream purification and lyophilization capacities. The combination significantly expands CordenPharma’s industrial footprint, adding a second US-based peptide manufacturing site and establishing a strategic presence in Shanghai, complementing its existing global network of 11 manufacturing and R&D facilities across Europe and North America. It also enhances supply chain flexibility for customers, offering multiple regional and global production models.

REFERENCES

Valuation range: EV 1b - 4b EUR

EBITDA range: 250M - 500M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of CORDENPHARMA by ASTORG are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Press release: view release

Target: cordenpharma

Acquirer: astorg